| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab.
|
Blood
|
2008
|
3.52
|
|
2
|
Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.
|
J Clin Oncol
|
2004
|
2.81
|
|
3
|
High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine.
|
J Clin Oncol
|
2005
|
2.62
|
|
4
|
Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial.
|
Lancet Oncol
|
2012
|
2.25
|
|
5
|
Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma.
|
Cancer
|
2003
|
2.21
|
|
6
|
Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma.
|
Br J Haematol
|
2013
|
2.01
|
|
7
|
Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma.
|
Br J Haematol
|
2010
|
1.85
|
|
8
|
Double hit lymphoma: the MD Anderson Cancer Center clinical experience.
|
Br J Haematol
|
2014
|
1.43
|
|
9
|
Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results.
|
Blood
|
2012
|
1.22
|
|
10
|
Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma.
|
Blood
|
2012
|
1.19
|
|
11
|
Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha.
|
Blood
|
2005
|
1.19
|
|
12
|
Tumorigenesis and aberrant signaling in transgenic mice expressing the human herpesvirus-8 K1 gene.
|
J Natl Cancer Inst
|
2002
|
1.18
|
|
13
|
Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma.
|
J Clin Oncol
|
2009
|
1.16
|
|
14
|
Activation of Src kinase Lyn by the Kaposi sarcoma-associated herpesvirus K1 protein: implications for lymphomagenesis.
|
Blood
|
2005
|
1.11
|
|
15
|
Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma.
|
Br J Haematol
|
2007
|
1.10
|
|
16
|
Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma.
|
Br J Haematol
|
2008
|
1.09
|
|
17
|
Phase II clinical trial of interleukin-12 in patients with relapsed and refractory non-Hodgkin's lymphoma and Hodgkin's disease.
|
Clin Cancer Res
|
2004
|
1.05
|
|
18
|
Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma.
|
Cancer
|
2008
|
1.01
|
|
19
|
The role of Skp2 in hematopoietic stem cell quiescence, pool size, and self-renewal.
|
Blood
|
2011
|
0.98
|
|
20
|
Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma.
|
J Clin Oncol
|
2004
|
0.95
|
|
21
|
Atiprimod inhibits the growth of mantle cell lymphoma in vitro and in vivo and induces apoptosis via activating the mitochondrial pathways.
|
Blood
|
2007
|
0.95
|
|
22
|
Mechanism of Fas signaling regulation by human herpesvirus 8 K1 oncoprotein.
|
J Natl Cancer Inst
|
2009
|
0.95
|
|
23
|
K1 protein of human herpesvirus 8 suppresses lymphoma cell Fas-mediated apoptosis.
|
Blood
|
2006
|
0.94
|
|
24
|
Phase I study of bortezomib plus ICE (BICE) for the treatment of relapsed/refractory Hodgkin lymphoma.
|
Br J Haematol
|
2011
|
0.92
|
|
25
|
The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma.
|
Br J Haematol
|
2014
|
0.91
|
|
26
|
Milatuzumab - a promising new immunotherapeutic agent.
|
Expert Opin Investig Drugs
|
2010
|
0.90
|
|
27
|
Nucleolin inhibits Fas ligand binding and suppresses Fas-mediated apoptosis in vivo via a surface nucleolin-Fas complex.
|
Blood
|
2013
|
0.88
|
|
28
|
The absolute monocyte and lymphocyte prognostic index for patients with diffuse large B-cell lymphoma who receive R-CHOP.
|
Clin Lymphoma Myeloma Leuk
|
2012
|
0.88
|
|
29
|
Treatment of benign lymphoid hyperplasia of the orbit with rituximab.
|
Ophthal Plast Reconstr Surg
|
2010
|
0.87
|
|
30
|
Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphoma.
|
Br J Haematol
|
2007
|
0.84
|
|
31
|
Decreased sensitivity of 17p-deleted chronic lymphocytic leukemia cells to a small molecule BCL-2 antagonist ABT-737.
|
Cancer
|
2011
|
0.84
|
|
32
|
Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo(®) ) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non-Hodgkin lymphomas.
|
Br J Haematol
|
2013
|
0.82
|
|
33
|
Thalidomide for patients with recurrent lymphoma.
|
Cancer
|
2004
|
0.81
|
|
34
|
PMLRARα binds to Fas and suppresses Fas-mediated apoptosis through recruiting c-FLIP in vivo.
|
Blood
|
2011
|
0.79
|
|
35
|
Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma.
|
Br J Haematol
|
2014
|
0.78
|
|
36
|
The peptide derived from the Ig-like domain of human herpesvirus 8 K1 protein induces death in hematological cancer cells.
|
J Exp Clin Cancer Res
|
2012
|
0.78
|
|
37
|
Cell Surface CD74-MIF Interactions Drive Melanoma Survival in Response to Interferon-γ.
|
J Invest Dermatol
|
2015
|
0.77
|
|
38
|
Doxorubicin, bleomycin, vinblastine and dacarbazine chemotherapy with interferon for advanced stage classic Hodgkin lymphoma: a 10-year follow-up study.
|
Leuk Lymphoma
|
2012
|
0.77
|
|
39
|
Pentostatin in T-non-Hodgkin's lymphomas: efficacy and effect on CD26+ T lymphocytes.
|
Oncol Rep
|
2003
|
0.75
|
|
40
|
Zoledronic acid for prevention of bone loss in patients receiving primary therapy for lymphomas: a prospective, randomized controlled phase III trial.
|
Clin Lymphoma Myeloma Leuk
|
2012
|
0.75
|
|
41
|
Clinical value of magnetic resonance imaging and other baseline testing for conjunctival mucosa-associated lymphoid tissue lymphoma.
|
Leuk Lymphoma
|
2013
|
0.75
|
|
42
|
Rates of Positive Findings on Positron Emission Tomography and Bone Marrow Biopsy in Patients With Ocular Adnexal Lymphoma.
|
Ophthal Plast Reconstr Surg
|
2016
|
0.75
|
|
43
|
Second-line 90Yttrium-ibritumomab tiuxetan (Zevalin) in a patient with conjunctival mucosa-associated lymphoid tissue lymphoma refractory to rituximab.
|
Ophthal Plast Reconstr Surg
|
2012
|
0.75
|